Gary Tse1,2, Christina Ip1,2, King Sum Luk1,2, Mengqi Gong3, Yan Yee Ting1,2, Ishan Lakhani1,2, George Bazoukis4, Guangping Li3, Konstantinos P Letsas4, Mei Dong5, Tong Liu3, Martin C S Wong6. 1. Department of Medicine and Therapeutics, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, China. 2. Faculty of Medicine, Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Hong Kong, China. 3. Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, China. 4. Laboratory of Cardiac Electrophysiology, Second Department of Cardiology, 'Evangelismos' General Hospital of Athens, Athens, Greece. 5. Department of Cardiology, Yantai Yuhuangding Hospital Affiliated to Qingdao University, Yantai, China. 6. JC School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, China.
Abstract
OBJECTIVES: Soluble suppression of tumorigenicity 2 (sST2) is a member of the interleukin-1 receptor family and a modulator of hypertrophic and fibrotic responses. Its prognostic value for patients undergoing aortic valve replacement (AVR) has been examined in prospective studies but to date, there has been no systematic evaluation or meta-analysis on this issue. METHODS: PubMed and Embase were searched until 1 October 2017 for studies that evaluated the relationship between sST2 levels and mortality after AVR. RESULTS: A total of 18 and 37 entries were retrieved from both databases, from which four studies were included in the final meta-analysis. In a total of 1154 subjects (50% male, mean age 80±10 years old, mean follow-up 14 months), elevated sST2 levels were significantly associated with a 44% increase in the risk of all-cause mortality (HR 1.44, 95% CI 1.30 to 1.60, p<0.0001; I2: 44%). CONCLUSIONS: sST2 significantly predicts all-cause mortality in patients who have undergone AVR, but this conclusion is limited by the small number of patients. Larger prospective studies are required to better elucidate its value for risk stratification in this patient population.
OBJECTIVES: Soluble suppression of tumorigenicity 2 (sST2) is a member of the interleukin-1 receptor family and a modulator of hypertrophic and fibrotic responses. Its prognostic value for patients undergoing aortic valve replacement (AVR) has been examined in prospective studies but to date, there has been no systematic evaluation or meta-analysis on this issue. METHODS: PubMed and Embase were searched until 1 October 2017 for studies that evaluated the relationship between sST2 levels and mortality after AVR. RESULTS: A total of 18 and 37 entries were retrieved from both databases, from which four studies were included in the final meta-analysis. In a total of 1154 subjects (50% male, mean age 80±10 years old, mean follow-up 14 months), elevated sST2 levels were significantly associated with a 44% increase in the risk of all-cause mortality (HR 1.44, 95% CI 1.30 to 1.60, p<0.0001; I2: 44%). CONCLUSIONS: sST2 significantly predicts all-cause mortality in patients who have undergone AVR, but this conclusion is limited by the small number of patients. Larger prospective studies are required to better elucidate its value for risk stratification in this patient population.
Authors: Michael Mildner; Angela Storka; Michael Lichtenauer; Veronika Mlitz; Minoo Ghannadan; Konrad Hoetzenecker; Stefanie Nickl; Balazs Dome; Erwin Tschachler; Hendrik Jan Ankersmit Journal: Cardiovasc Res Date: 2010-04-02 Impact factor: 10.787
Authors: Benjamin Dieplinger; Margot Egger; Meinhard Haltmayer; Marcus E Kleber; Hubert Scharnagl; Guenther Silbernagel; Rudolf A de Boer; Winfried Maerz; Thomas Mueller Journal: Clin Chem Date: 2014-01-08 Impact factor: 8.327
Authors: Ellen O Weinberg; Masahisa Shimpo; Shelley Hurwitz; Shin-ichi Tominaga; Jean-Lucien Rouleau; Richard T Lee Journal: Circulation Date: 2003-02-11 Impact factor: 29.690
Authors: Svitlana Demyanets; Christoph Kaun; Richard Pentz; Konstantin A Krychtiuk; Sabine Rauscher; Stefan Pfaffenberger; Andreas Zuckermann; Arezu Aliabadi; Marion Gröger; Gerald Maurer; Kurt Huber; Johann Wojta Journal: J Mol Cell Cardiol Date: 2013-04-06 Impact factor: 5.000
Authors: Atul Anand; Catherine Harley; Akila Visvanathan; Anoop S V Shah; Joanna Cowell; Alasdair MacLullich; Susan Shenkin; Nicholas L Mills Journal: Eur Heart J Qual Care Clin Outcomes Date: 2017-04-01
Authors: Christina Ip; King Sum Luk; Vincent Lok Cheung Yuen; Lorraine Chiang; Ching Ki Chan; Kevin Ho; Mengqi Gong; Teddy Tai Loy Lee; Keith Sai Kit Leung; Leonardo Roever; George Bazoukis; Konstantinos Lampropoulos; Ka Hou Christien Li; Gary Tse; Tong Liu Journal: Int J Cardiol Heart Vasc Date: 2021-10-18